Your (or your loved one’s) medical records contain clues that can lead to new treatments.
AllStripes researchers learn from patient records what would truly improve quality of life.
Using cutting-edge tech we analyze your community’s data to improve trial design and chances of success.
Your community’s de-identified records can advance multiple treatment studies.
We do the work to collect all your records, at no cost, in your secure account. Access doctors’ notes you’ve never seen.
See how your rare disease journey compares to others with your condition, and what’s helping.
We’ll send you exclusive updates on the studies you’re contributing to and how you’re driving forward research.
Hemolytic disease of the fetus and newborn (HDFN) is a blood disorder that occurs when the blood types of a mother and fetus are incompatible. Women who are exposed to a blood type different from their own, usually from a blood transfusion or a pregnancy, can create antibodies to destroy the foreign red blood cells. If the woman becomes pregnant with a fetus who has an incompatible blood type, her antibodies can cross the placenta and destroy the fetus’ red blood cells. This may cause symptoms such as anemia, enlarged organs, or hydrops in the fetus. After birth, babies with HDFN may experience anemia, hyperbilirubinemia (excess bilirubin in the blood caused by red blood cells breaking down too rapidly), jaundice, neutropenia or thrombocytopenia after birth.
Some babies with HDFN have no symptoms, while other babies are severely affected and may die during the second or third trimester or after birth. However, with close monitoring and timely treatment, babies with HDFN have a high rate of survival.
The latest on our research: We are jumpstarting our Alloimmunization & HDFN program to accelerate research on the condition and welcome all parents and caregivers interested in participating and spreading the word to the Alloimmunization & HDFN community.
1. Sign up
Create your private account and review our research consent (takes about 10 minutes)
2. We get to work
We do all the behind-the-scenes work to retrieve and process your records
3. Impact research
Power multiple research projects at once by contributing your de-identified data
Still have questions?
Check out our FAQsWe believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.
We abide by a strict research consent and privacy policy. We only share de-identified data with researchers, foundations, and therapeutic companies with patients’ consent. Protecting the privacy of patients and ensuring the security of their information is our highest priority.
We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.
We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.
Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.